Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1
Open Access
- 16 November 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11), 3684
- https://doi.org/10.3390/jcm9113684
Abstract
Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they have adverse side effects. Here, we expressed 60-residue (NH2NAE…IEKCOOH) Kunitz domain1 (KD1) mutants of human tissue factor pathway inhibitor type-2 that inhibit plasmin as well as plasminogen activation. A single (KD1-L17R-KCOOH) and a double mutant (KD1-Y11T/L17R- KCOOH) were expressed in Escherichia coli as His-tagged constructs, each with enterokinase cleavage sites. KD1-Y11T/L17R-KCOOH was also expressed in Pichia pastoris. KD1-Y11T/L17R-KCOOH inhibited plasmin comparably to aprotinin and bound to the kringle domains of plasminogen/plasmin and tPA with Kd of ~50 nM and ~35 nM, respectively. Importantly, compared to aprotinin, KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH did not inhibit kallikrein. Moreover, the antifibrinolytic potential of KD1-Y11T/L17R-KCOOH was better than that of KD1-L17R-KCOOH and similar to that of aprotinin in plasma clot-lysis assays. In thromboelastography experiments, KD1-Y11T/L17R-KCOOH was shown to inhibit fibrinolysis in a dose dependent manner and was comparable to aprotinin at a higher concentration. Further, KD1-Y11T/L17R-KCOOH did not induce cytotoxicity in primary human endothelial cells or fibroblasts. We conclude that KD1-Y11T/L17R-KCOOH is comparable to aprotinin, the most potent known inhibitor of plasmin and can be produced in large amounts using Pichia.This publication has 52 references indexed in Scilit:
- Tranexamic acid concentrations associated with human seizures inhibit glycine receptorsJCI Insight, 2012
- A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial)The Journal of Thoracic and Cardiovascular Surgery, 2012
- Are tranexamic acid and ε-aminocaproic acid adequate substitutes for aprotinin?Annals of Cardiac Anaesthesia, 2012
- Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiencyClinical, Cosmetic and Investigational Dermatology, 2011
- Seizures After Open Heart Surgery: Comparison of ε-Aminocaproic Acid and Tranexamic AcidJournal of Cardiothoracic and Vascular Anesthesia, 2011
- Engineering Kunitz Domain 1 (KD1) of Human Tissue Factor Pathway Inhibitor-2 to Selectively Inhibit FibrinolysisPublished by Elsevier BV ,2011
- Aprotinin in Cardiac Surgery: A Different Point of ViewThe Heart Surgery Forum, 2008
- In vivo significance of kinetic constants of protein proteinase inhibitorsBiochemical Medicine, 1984
- The effect of aprotinin (a serine protease inhibitor) on renal function and renin release.Hypertension, 1983
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970